194 related articles for article (PubMed ID: 20133499)
1. Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions.
Shankaran V; Obel J; Benson AB
Oncologist; 2010; 15(2):157-67. PubMed ID: 20133499
[TBL] [Abstract][Full Text] [Related]
2. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
4. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.
Baas JM; Krens LL; Guchelaar HJ; Morreau H; Gelderblom H
Oncologist; 2011; 16(9):1239-49. PubMed ID: 21742964
[TBL] [Abstract][Full Text] [Related]
5. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
[TBL] [Abstract][Full Text] [Related]
6. Optimization of
Santos C; Azuara D; Garcia-Carbonero R; Alfonso PG; Carrato A; Elez ME; Gomez A; Losa F; Montagut C; Massuti B; Navarro V; Varela M; Lopez-Doriga A; Moreno V; Valladares M; Manzano JL; Vieitez JM; Aranda E; Sanjuan X; Tabernero J; Capella G; Salazar R
Mol Cancer Ther; 2017 Sep; 16(9):1999-2007. PubMed ID: 28626084
[TBL] [Abstract][Full Text] [Related]
7. Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.
Azuara D; Santos C; Lopez-Doriga A; Grasselli J; Nadal M; Sanjuan X; Marin F; Vidal J; Montal R; Moreno V; Bellosillo B; Argiles G; Elez E; Dienstmann R; Montagut C; Tabernero J; Capellá G; Salazar R
Mol Cancer Ther; 2016 May; 15(5):1106-12. PubMed ID: 27037411
[TBL] [Abstract][Full Text] [Related]
8. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients.
Zlobec I; Molinari F; Kovac M; Bihl MP; Altermatt HJ; Diebold J; Frick H; Germer M; Horcic M; Montani M; Singer G; Yurtsever H; Zettl A; Terracciano L; Mazzucchelli L; Saletti P; Frattini M; Heinimann K; Lugli A
Br J Cancer; 2010 Jan; 102(1):151-61. PubMed ID: 19935791
[TBL] [Abstract][Full Text] [Related]
10. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.
Jeong WJ; Cha PH; Choi KY
World J Gastroenterol; 2014 Aug; 20(29):9862-71. PubMed ID: 25110417
[TBL] [Abstract][Full Text] [Related]
11. MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.
Chuang J; Wang C; Guo Y; Valenzuela V; Wu J; Fakih M
Clin Colorectal Cancer; 2021 Mar; 20(1):72-78. PubMed ID: 33436306
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
Soeda H; Shimodaira H; Watanabe M; Suzuki T; Gamoh M; Mori T; Komine K; Iwama N; Kato S; Ishioka C
Int J Clin Oncol; 2013 Aug; 18(4):670-7. PubMed ID: 22638623
[TBL] [Abstract][Full Text] [Related]
13. Clinical Impact of Primary Tumor Location and
Sato T; Osumi H; Shinozaki E; Ooki A; Shimozaki K; Kamiimabeppu D; Nakayama I; Wakatsuki T; Ogura M; Takahari D; Chin K; Yamaguchi K
Anticancer Res; 2021 Aug; 41(8):3905-3915. PubMed ID: 34281853
[TBL] [Abstract][Full Text] [Related]
14. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.
Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Watanabe T; Sugiyama M
Cancer Chemother Pharmacol; 2014 Apr; 73(4):749-57. PubMed ID: 24500024
[TBL] [Abstract][Full Text] [Related]
16. The Developing Role of Anti-Epidermal Growth Factor Receptor Agents in the Treatment of Advanced or Metastatic Colorectal Cancer.
Ursem C; Venook AP
Oncology (Williston Park); 2017 Nov; 31(11):785-8, 802. PubMed ID: 29179247
[TBL] [Abstract][Full Text] [Related]
17. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review.
Unim B; Pitini E; De Vito C; D'Andrea E; Marzuillo C; Villari P
Value Health; 2020 Jan; 23(1):114-126. PubMed ID: 31952666
[TBL] [Abstract][Full Text] [Related]
20. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
